Sandbox mona cor: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 1: Line 1:


{{PBI|Human papillomavirus}}
{{PBI|Influenza A}}
{
{PBI|Influenza B}}


:* 1.'''T. vaginalis infection in adults''' <ref>{{cite web | title =trichomoniasis | url =  http://www.cdc.gov/std/tg2015/trichomoniasis.htm  }}</ref>
:* 1.'''T. vaginalis infection in adults''' <ref>{{cite web | title =trichomoniasis | url =  http://www.cdc.gov/std/tg2015/trichomoniasis.htm  }}</ref>
:* Preferred regimen: [[Metronidazole]] 2 g PO in a single dose
::* Preferred regimen (1): [[Metronidazole]] 2 g PO in a single dose
 
::* Preferred regimen (2): [[Tinidazole]] 2 g PO in a single dose
:* Preferred regimen: [[Tinidazole]] 2 g PO in a single dose
::* Alternative regimen: [[Metronidazole]] 500  mg PO bid for 7 days
:* Alternative regimen: [[Metronidazole]] 500  mg PO bid for 7 days


:* 2. '''T. vaginalis infection in Pregnant and Lactating Women'''
:* 2. '''T. vaginalis infection in Pregnant and Lactating Women'''
Line 30: Line 23:
:::* Preferred regimen: [[Metronidazole]] 500  mg PO bid for 7 days
:::* Preferred regimen: [[Metronidazole]] 500  mg PO bid for 7 days
::* 4.2 '''Treatment failure again'''
::* 4.2 '''Treatment failure again'''
:::* Preferred regimen: [[Metronidazole]] 2 g PO for 7 days  
:::* Preferred regimen (1): [[Metronidazole]] 2 g PO for 7 days  
 
:::* Preferred regimen (2): [[Tinidazole]] 2 g PO for 7 days  
:::* Preferred regimen: [[Tinidazole]] 2 g PO for 7 days  
::* 4.3 '''Nitroimidazole-resistant cases'''
::* 4.3 '''Nitroimidazole-resistant cases'''
:::* Preferred regimen: [[Tinidazole]] 2-3 g PO for 14 days
:::* Preferred regimen: [[Tinidazole]] 2-3 g PO for 14 days
Line 39: Line 31:
* ''' Sleeping sickness'''<ref>{{cite web|title=African Trypanosomiasis| url=  http://www.cdc.gov/parasites/sleepingsickness/health_professionals/index.html}}</ref>   
* ''' Sleeping sickness'''<ref>{{cite web|title=African Trypanosomiasis| url=  http://www.cdc.gov/parasites/sleepingsickness/health_professionals/index.html}}</ref>   
:*1. '''East African trypanosomiasis'''
:*1. '''East African trypanosomiasis'''
:* 1.1'''T. b. rhodesiense, hemolymphatic stage'''
:* 1.1 '''T. b. rhodesiense, hemolymphatic stage'''
::* ''' Adult '''
::* 1.1.1 ''' Adult '''
:::* Preferred regimen: [[Suramin]] 1 gm IV on days 1,3,5,14, and 21
:::* Preferred regimen: [[Suramin]] 1 gm IV on days 1,3,5,14, and 21
::* '''Pediatric'''  
::* 1.1.2 '''Pediatric'''  
:::* Preferred regimen: [[Suramin]]  20 mg/kg IV on days 1, 3, 5, 14, and 21
:::* Preferred regimen: [[Suramin]]  20 mg/kg IV on days 1, 3, 5, 14, and 21
:*1.2 '''T. b. rhodesiense, CNS involvement'''
:*1.2 '''T. b. rhodesiense, CNS involvement'''
::* ''' Adult'''
::* 1.2.1 ''' Adult'''
:::* Preferred regimen: [[Melarsoprol]] 2-3.6 mg/kg/day IV for 3 days.After 7 days, 3.6 mg/kg/day for 3 days. Give a 3rd series of 3.6 mg/kg/d after 7 days.
:::* Preferred regimen: [[Melarsoprol]] 2-3.6 mg/kg/day IV for 3 days.After 7 days, 3.6 mg/kg/day for 3 days. Give a 3rd series of 3.6 mg/kg/d after 7 days.
::* ''' Pediatric'''
::* 1.2.2 ''' Pediatric'''
:::* Preferred regimen: [[Melarsoprol]]  2-3.6 mg/kg/day IV for 3 days.After 7 days, 3.6 mg/kg/day for 3 days. Give a 3rd series of 3.6 mg/kg/d after 7 days  
:::* Preferred regimen: [[Melarsoprol]]  2-3.6 mg/kg/day IV for 3 days.After 7 days, 3.6 mg/kg/day for 3 days. Give a 3rd series of 3.6 mg/kg/d after 7 days  


:* 2. '''West African trypanosomiasis'''
:* 2. '''West African trypanosomiasis'''
:* 2.1 '''T. b. gambiense, Hemolymphatic stage'''
:* 2.1 '''T. b. gambiense, Hemolymphatic stage'''
::* ''' Adult'''
::* 2.1.1 ''' Adult'''
:::* Preferred regimen: [[Pentamidine]] 4 mg/kg/day IM/ IV for 7-10 days
:::* Preferred regimen: [[Pentamidine]] 4 mg/kg/day IM/ IV for 7-10 days
::* '''Pediatric'''
::* 2.1.2 '''Pediatric'''
:::* Preferred regimen: [[Pentamidine]] 4 mg/kg/day IM/IV for 7-10 days
:::* Preferred regimen: [[Pentamidine]] 4 mg/kg/day IM/IV for 7-10 days
::::* Note (1): Pentamidine should be used during pregnancy and lacation  only if the potential benefit justifies the potential risk  
::::* Note (1): Pentamidine should be used during pregnancy and lacation  only if the potential benefit justifies the potential risk  
::::* Note (2): IM/IV Pentamidine have a similar safety profile in children age 4 months and older as in adults. Pentamidine is listed as a medicine for the treatment of 1st stage African trypanosomiasis infection (Trypanosoma brucei gambiense) on the WHO Model List of Essential Medicines for Children, intended for the use of children up to 12 years of age.
::::* Note (2): IM/IV Pentamidine have a similar safety profile in children age 4 months and older as in adults. Pentamidine is listed as a medicine for the treatment of 1st stage African trypanosomiasis infection (Trypanosoma brucei gambiense) on the WHO Model List of Essential Medicines for Children, intended for the use of children up to 12 years of age.
:* '''2.2 T. b. gambiense, CNS involvement'''
:* '''2.2 T. b. gambiense, CNS involvement'''
::*''' Adult'''  
::* 2.2.1 ''' Adult'''  
:::* Preferred regimen: [[Eflornithine]] 400 mg/kg/day in 4 doses for 14 days
:::* Preferred regimen: [[Eflornithine]] 400 mg/kg/day in 4 doses for 14 days
::* '''Pediatric'''
::* 2.2.2 '''Pediatric'''
 
:::* Preferred regimen: [[Eflornithine]] 400 mg/kg/day in 4 doses for 14 days
:::* Preferred regimen: [[Eflornithine]] 400 mg/kg/day in 4 doses for 14 days
:::*  Note (1): [[Eflornithine]] should be used during pregnancy and lactation, only if the potential benefit justifies the potential risk  
:::*  Note (1): [[Eflornithine]] should be used during pregnancy and lactation, only if the potential benefit justifies the potential risk  

Revision as of 15:34, 17 July 2015


  • 1.T. vaginalis infection in adults [1]
  • 2. T. vaginalis infection in Pregnant and Lactating Women
  • 2.1 Pregnant women
  • 2.2 Post-partum and Breastfeeding
  • Note (2): Symptomatic pregnant women, regardless of pregnancy stage, should be tested and considered for treatment. Pregnant women should be advised of the risk and benefits to treatment as infection (definitely) and treatment (possibly)
  • Note (3): Pregnant women with HIV who are treated for T. vaginalis infection should be retested 3 months after treatment.
  • 3.T. vaginalis infection in patients with HIV
  • 4. Persistent or Recurrent Trichomoniasis
  • 4.1 Treatment Failure
  • 4.2 Treatment failure again
  • 4.3 Nitroimidazole-resistant cases
  • Preferred regimen: Tinidazole 2-3 g PO for 14 days
  • 1. East African trypanosomiasis
  • 1.1 T. b. rhodesiense, hemolymphatic stage
  • 1.1.1 Adult
  • Preferred regimen: Suramin 1 gm IV on days 1,3,5,14, and 21
  • 1.1.2 Pediatric
  • Preferred regimen: Suramin 20 mg/kg IV on days 1, 3, 5, 14, and 21
  • 1.2 T. b. rhodesiense, CNS involvement
  • 1.2.1 Adult
  • Preferred regimen: Melarsoprol 2-3.6 mg/kg/day IV for 3 days.After 7 days, 3.6 mg/kg/day for 3 days. Give a 3rd series of 3.6 mg/kg/d after 7 days.
  • 1.2.2 Pediatric
  • Preferred regimen: Melarsoprol 2-3.6 mg/kg/day IV for 3 days.After 7 days, 3.6 mg/kg/day for 3 days. Give a 3rd series of 3.6 mg/kg/d after 7 days
  • 2. West African trypanosomiasis
  • 2.1 T. b. gambiense, Hemolymphatic stage
  • 2.1.1 Adult
  • Preferred regimen: Pentamidine 4 mg/kg/day IM/ IV for 7-10 days
  • 2.1.2 Pediatric
  • Preferred regimen: Pentamidine 4 mg/kg/day IM/IV for 7-10 days
  • Note (1): Pentamidine should be used during pregnancy and lacation only if the potential benefit justifies the potential risk
  • Note (2): IM/IV Pentamidine have a similar safety profile in children age 4 months and older as in adults. Pentamidine is listed as a medicine for the treatment of 1st stage African trypanosomiasis infection (Trypanosoma brucei gambiense) on the WHO Model List of Essential Medicines for Children, intended for the use of children up to 12 years of age.
  • 2.2 T. b. gambiense, CNS involvement
  • 2.2.1 Adult
  • Preferred regimen: Eflornithine 400 mg/kg/day in 4 doses for 14 days
  • 2.2.2 Pediatric
  • Preferred regimen: Eflornithine 400 mg/kg/day in 4 doses for 14 days
  • Note (1): Eflornithine should be used during pregnancy and lactation, only if the potential benefit justifies the potential risk
  • Note (2): The safety of Eflornithine in children has not been established. Eflornithine is not approved by the Food and Drug Administration (FDA) for use in pediatric patients. Eflornithine is listed for the treatment of 1st stage African trypanosomiasis inTrypanosoma brucei gambiense infection on the WHO Model List of Essential Medicines for Children, intended for the use of children up to 12 years of age.
  • 1.Preferred regimen(1):Benznidazole < 12 years5-7.5 mg/kg per day orally in 2 divided doses for 60 days

12 years or older5-7 mg/kg per day orally in 2 divided doses for 60 days

  • 2.Preferred regimen(2): Nifurtimox ≤ 10 years15-20 mg/kg per day orally in 3 or 4 divided doses for 90 days

11-16 years12.5-15 mg/kg per day orally in 3 or 4 divided doses for 90 days 17 years or older8-10 mg/kg per day orally in 3 or 4 divided doses for 90 days

  • Note: In the United States, nifurtimox and benznidazole are not FDA approved and are available only from CDC under investigational protocols.


=Parasites – Intestinal Nematodes (Roundworms)

  1. "trichomoniasis".
  2. "African Trypanosomiasis".